Despite the absence of EGFR-positive NSCLC patients in most clinical trials evaluating ICIs and platinum-doublet combination chemotherapy, the IMpower150 trial uniquely included non-squamous NSCLC patients with EGFR mutations or ALK rearrangements [7,8]. This evidence concerns the gene ALK and non-small cell lung carcinoma.